Background: The aim of this study was to investigate the impact of anti-HBc (HBcAb) positivity on the progression of liver fibrosis (Fibrosis-4 score >3.25) in the Italian cohort of HIV-infected individuals naïve to antiretroviral treatment (ICONA). Methods: All patients with FIB-4 <3.25 at baseline were evaluated prospectively: 6966 people with HIV (PWH) were screened and classified based on hepatitis B virus (HBV) and hepatitis C virus (HCV) serology. Results: Patients who were HBcAb+/HCV-/HBs antigen (HBsAg)-and HCV+/HBcAb+/HBsAg-or HBsAg+/HBcAb+/HCV-had CD4+ cell counts below the nadir and significantly higher prevalence of AIDS diagnosis at baseline than the other groups (P <. 0001). A Cox regression model adjusted for age, HIV transmission mode, country of birth, and alcohol consumption showed a higher relative risk (HR) of progression to FIB-4 >3.25 in HCV+/HBcAb+/HBsAg-patients (HR, 7.2; 95% CI, 3 8-13.64). Conclusions: HBcAb+ contributes to liver damage in HIV+/HCV+/HBcAb+/HBsAg-subjects. A careful monitoring for signs of previous HBV infection is needed in this kind of patients.

HBcAb positivity increases the risk of severe hepatic fibrosis development in HIV/HCV-positive subjects from the ICONA Italian cohort of HIV-infected patients / V. Malagnino, C. Cerva, A. Cingolani, F. Ceccherini-Silberstein, A. Vergori, G. Cuomo, C.F. Perno, M. Puoti, A. D'Arminio Monforte, A. Cozzi-Lepri, M. Andreoni, L. Sarmati. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 8:1(2021 Jan), pp. ofaa566.1-ofaa566.8. [10.1093/ofid/ofaa566]

HBcAb positivity increases the risk of severe hepatic fibrosis development in HIV/HCV-positive subjects from the ICONA Italian cohort of HIV-infected patients

C.F. Perno;A. D'Arminio Monforte;
2021

Abstract

Background: The aim of this study was to investigate the impact of anti-HBc (HBcAb) positivity on the progression of liver fibrosis (Fibrosis-4 score >3.25) in the Italian cohort of HIV-infected individuals naïve to antiretroviral treatment (ICONA). Methods: All patients with FIB-4 <3.25 at baseline were evaluated prospectively: 6966 people with HIV (PWH) were screened and classified based on hepatitis B virus (HBV) and hepatitis C virus (HCV) serology. Results: Patients who were HBcAb+/HCV-/HBs antigen (HBsAg)-and HCV+/HBcAb+/HBsAg-or HBsAg+/HBcAb+/HCV-had CD4+ cell counts below the nadir and significantly higher prevalence of AIDS diagnosis at baseline than the other groups (P <. 0001). A Cox regression model adjusted for age, HIV transmission mode, country of birth, and alcohol consumption showed a higher relative risk (HR) of progression to FIB-4 >3.25 in HCV+/HBcAb+/HBsAg-patients (HR, 7.2; 95% CI, 3 8-13.64). Conclusions: HBcAb+ contributes to liver damage in HIV+/HCV+/HBcAb+/HBsAg-subjects. A careful monitoring for signs of previous HBV infection is needed in this kind of patients.
anti-HBc; HBV; HIV/HBV coinfection; liver fibrosis; OBI
Settore MED/17 - Malattie Infettive
gen-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
ofaa566.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 231.89 kB
Formato Adobe PDF
231.89 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/898482
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 2
social impact